title: [Level of evidence for therapeutic drug monitoring of aminoglycosides].
abstract: Aminoglycosides are major antibiotics indicated for the treatment of infection with gram-negative bacilli. They are characterized by high clinical effectiveness but their main drawback is the occurrence of toxicity in a significant number of patients. Pharmacokinetic parameters of aminoglycosides exhibit wide inter-individual variability and the relationships between concentration and effect have been clearly demonstrated. Consistent studies have demonstrated that therapeutic drug monitoring (TDM) of aminoglycosides administered in multiple daily doses was cost-effective in maximising antibiotic efficacy and/or reducing incidence of toxicity. Therefore TDM of aminoglycosides should be considered "essential". Level of evidence for TDM of aminoglycosides administered once daily is not so clearly demonstrated however it should be highly recommended.
authors.affiliation: Service de Toxicologie et Pharmacocinétique, CHU, Poitiers, France. n.venisse@chu--poitiers.fr
authors.forename: Nicolas
authors.initials: N
authors.lastname: Venisse
authors.forename: Audrey
authors.initials: A
authors.lastname: Boulamery
mesh_terms: D000617:Aminoglycosides / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000191:economics / Q000382:microbiology; D003362:Cost-Benefit Analysis; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring / Q000379:methods*; D019317:Evidence-Based Medicine; D006801:Humans; D007262:Infusions, Intravenous; D007674:Kidney Diseases / Q000150:complications / Q000378:metabolism
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents